Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company whose primary drug candidate, resmetirom, was developed for the treatment of NASH (non-alcoholic steatohepatitis). The development pathway for this and other pharmaceutical candidates inherently requires animal testing to satisfy regulatory requirements for safety and efficacy prior to human trials. The company's own Supplier Code of Conduct acknowledges this activity, stating compliance with laws governing animal care and use.

The available evidence, including an FDA FOIA log referencing the company, indicates Madrigal conducts or sponsors animal studies as part of its drug development process. These studies are performed under the U.S. Department of Agriculture's Animal Welfare Act and FDA Good Laboratory Practice (GLP) regulations, which are standard for the industry. The company’s SEC filings note the completion of animal safety studies as a routine step in advancing its lead product candidate toward market approval. This places the company within the broad pharmaceutical sector practice of animal testing for regulatory compliance and product development.